CI Investments Inc. Purchases Shares of 301,381 Novo Nordisk A/S (NVO)

CI Investments Inc. purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 301,381 shares of the company’s stock, valued at approximately $14,511,000.

Several other large investors have also recently made changes to their positions in the company. BTC Capital Management Inc. boosted its stake in shares of Novo Nordisk A/S by 69.9% during the 3rd quarter. BTC Capital Management Inc. now owns 8,730 shares of the company’s stock worth $420,000 after acquiring an additional 3,592 shares in the last quarter. Cabot Wealth Management Inc. boosted its position in Novo Nordisk A/S by 1.2% in the 3rd quarter. Cabot Wealth Management Inc. now owns 112,475 shares of the company’s stock valued at $5,416,000 after buying an additional 1,312 shares during the last quarter. Sei Investments Co. boosted its position in Novo Nordisk A/S by 7.9% in the 3rd quarter. Sei Investments Co. now owns 18,509 shares of the company’s stock valued at $891,000 after buying an additional 1,358 shares during the last quarter. GW Henssler & Associates Ltd. boosted its position in Novo Nordisk A/S by 6.3% in the 3rd quarter. GW Henssler & Associates Ltd. now owns 129,976 shares of the company’s stock valued at $6,258,000 after buying an additional 7,759 shares during the last quarter. Finally, Global X MANAGEMENT CO LLC boosted its position in Novo Nordisk A/S by 5.3% in the 3rd quarter. Global X MANAGEMENT CO LLC now owns 111,977 shares of the company’s stock valued at $5,392,000 after buying an additional 5,646 shares during the last quarter. 6.01% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by Markets Daily and is owned by of Markets Daily. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.themarketsdaily.com/2017/11/14/ci-investments-inc-purchases-shares-of-301381-novo-nordisk-as-nvo.html.

Shares of Novo Nordisk A/S (NYSE:NVO) traded down $0.15 during trading on Tuesday, hitting $49.76. 895,100 shares of the stock were exchanged, compared to its average volume of 2,158,519. The firm has a market cap of $127,270.50, a price-to-earnings ratio of 21.80, a PEG ratio of 2.98 and a beta of 0.63. Novo Nordisk A/S has a 1-year low of $30.89 and a 1-year high of $50.95.

In related news, insider Eric S. Sprott bought 50,000 shares of the business’s stock in a transaction dated Wednesday, November 8th. The shares were acquired at an average price of $8.34 per share, for a total transaction of $417,000.00.

A number of equities analysts have weighed in on the stock. BidaskClub raised shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research report on Saturday, August 12th. BNP Paribas cut shares of Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a research report on Monday, September 25th. Zacks Investment Research cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, July 17th. Finally, Bank of America Corporation raised shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research report on Wednesday, September 6th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $55.00.

About Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply